All AstroNova Stakeholders Invited to Meet and Interact with Askeladden’s Board Candidates Askeladden Nominees Have Specific ...

The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Furthermore, ...

The letter expressed concerns about recent organizational and financial developments and urged Senate and House committees to investigate ...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology ...